Hefei Yifan Pharmaceutical

Yifan Pharmaceutical is a leading Chinese pharmaceutical company headquartered in Hefei, specializing in the development, manufacturing, and global commercialization of innovative biologics and high-quality small molecule drugs. The company achieved a significant milestone with the FDA approval of Ryzneuta (efbemalenograstim alfa), a novel long-acting G-CSF for chemotherapy-induced neutropenia, developed through its subsidiary Evive Biotech. Yifan maintains a diverse portfolio across therapeutic areas including oncology, hematology, dermatology, and gynecology, integrating traditional Chinese medicine with modern biotechnology. With a robust global R&D network and large-scale GMP manufacturing facilities, the company is focused on expanding its footprint in highly regulated markets such as the United States and Europe.